Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101


Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy.

Matsuo N, Azuma K, Sasada T.

Oncotarget. 2019 Mar 8;10(20):1866-1867. doi: 10.18632/oncotarget.26749. eCollection 2019 Mar 8. No abstract available.


Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.

Iiizumi S, Ohtake J, Murakami N, Kouro T, Kawahara M, Isoda F, Hamana H, Kishi H, Nakamura N, Sasada T.

Cancers (Basel). 2019 Feb 24;11(2). pii: E266. doi: 10.3390/cancers11020266.


A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M.

Neuro Oncol. 2018 Nov 30. doi: 10.1093/neuonc/noy200. [Epub ahead of print]


Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.

Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T.

Oncotarget. 2018 Sep 25;9(75):34066-34078. doi: 10.18632/oncotarget.26122. eCollection 2018 Sep 25.


Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.

Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T.

Int J Cancer. 2019 Mar 1;144(5):1170-1179. doi: 10.1002/ijc.31923. Epub 2018 Nov 12.


Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer.

Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, Shirabe K, Kuwano H, Yamaue H.

Oncotarget. 2018 Jul 31;9(59):31448-31458. doi: 10.18632/oncotarget.25837. eCollection 2018 Jul 31.


Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.

Ono T, Azuma K, Kawahara A, Sasada T, Matsuo N, Kakuma T, Kamimura H, Maeda R, Hattori C, On K, Nagata K, Sato F, Chitose SI, Shin B, Aso T, Akiba J, Umeno H.

Head Neck. 2018 Sep;40(9):2007-2019. doi: 10.1002/hed.25189. Epub 2018 May 13.


Use of patient-derived xenograft mouse models in cancer research and treatment.

Yada E, Wada S, Yoshida S, Sasada T.

Future Sci OA. 2017 Dec 7;4(3):FSO271. doi: 10.4155/fsoa-2017-0136. eCollection 2018 Mar. No abstract available.


Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.

Ono T, Azuma K, Kawahara A, Sasada T, Hattori S, Sato F, Shin B, Chitose SI, Akiba J, Hirohito U.

Oncotarget. 2017 Oct 6;8(54):92699-92714. doi: 10.18632/oncotarget.21564. eCollection 2017 Nov 3.


Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.

Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T.

Oncotarget. 2017 Jun 27;8(37):61618-61625. doi: 10.18632/oncotarget.18651. eCollection 2017 Sep 22.


Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.

Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M.

Cancer Sci. 2017 Dec;108(12):2430-2437. doi: 10.1111/cas.13404. Epub 2017 Oct 12.


Are peptide vaccines viable in combination with other cancer immunotherapies?

Ohtake J, Sasada T.

Future Oncol. 2017 Aug;13(18):1577-1580. doi: 10.2217/fon-2017-0136. Epub 2017 Aug 4. No abstract available.


Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.

Yutani S, Shirahama T, Muroya D, Matsueda S, Yamaguchi R, Morita M, Shichijo S, Yamada A, Sasada T, Itoh K.

Cancer Sci. 2017 Sep;108(9):1732-1738. doi: 10.1111/cas.13301. Epub 2017 Jul 23.


Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.

Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T.

Clin Lung Cancer. 2017 Nov;18(6):e385-e394. doi: 10.1016/j.cllc.2017.03.011. Epub 2017 Mar 24.


Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females.

Yokomine M, Matsueda S, Kawano K, Sasada T, Fukui A, Yamashita T, Komatsu N, Shichijo S, Tasaki K, Matsukuma K, Itoh K, Kamura T, Ushijima K.

Exp Ther Med. 2017 Apr;13(4):1500-1505. doi: 10.3892/etm.2017.4150. Epub 2017 Feb 21.


Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13.


A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.

Shirahama T, Muroya D, Matsueda S, Yamada A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K, Sasada T, Yutani S.

Cancer Sci. 2017 May;108(5):838-845. doi: 10.1111/cas.13193. Epub 2017 May 5.


Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K.

Cancer Sci. 2017 Apr;108(4):598-603. doi: 10.1111/cas.13189. Epub 2017 Apr 21.


Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations.

Sasada T.

Nihon Rinsho. 2017 Feb;75(2):189-195. Review. Japanese.


Supplemental Content

Loading ...
Support Center